VEGFA and ovarian carcinoma: Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), has been recently incorporated in the treatment of ovarian cancer patients after multiple clinical trials have proven its clinical benefit, even for cisplatin resistant recurrent ovarian cancer (3, 4).